Gina Mauro | Authors


Early Promise Is Seen With CTX130 for RCC

January 18, 2023

According to findings from the phase 1 COBALT-RCC trial, CTX130 led to an objective response rate of 8%, a stable disease rate of 69%, and a disease control rate of 77% in patients with advanced clear cell renal cell carcinoma.